2641-P: Clinically Significant Changes in Body Composition with Treatment of Obesity in Older Adults, 65+, with and without Diabetes

Introduction and Objective: Aging related changes in body composition, especially muscle mass loss, may be exacerbated by use of incretin medications for weight loss and type 2 diabetes (T2D). Body composition assessment allows for assessment of changes in muscle and fat mass in addition to weight and BMI, which may be particularly important in older adults. Objective: To evaluate changes in body composition in individuals ≥ 65 years referred for treatment of obesity, with and without T2D. Methods: The TANITA MC-780U BIA scale was used for body composition analysis; measures included % adiposity, visceral adiposity score (VAS), fat, muscle, and bone mass. Statistical analyses were stratified by diabetes status and incretin use (STATA vBE18.5). Results: The study group, n=112, mean age 70±5 yrs, was 80% female, 77% non-Hispanic white, 21% black, 1% Hispanic. T2D was present in 29%. Baseline mean BMI was 34.8±6.5 kg/m2 and %adiposity 39.8±7.2%. Weight, BMI, fat mass, %adiposity, and VAS significantly decreased but muscle and bone mass also decreased (Table 1). Incretin use (72%) was associated with lower weight (p=0.04) and BMI (p=0.02). Body composition changes in those with and without diabetes were variable. Conclusion: More precise assessment of changes in muscle and fat mass may inform more therapeutic targets to optimize muscle mass and physical function as well as reducing cardiometabolic risk through loss of total and central adiposity. Disclosure A. Johnson-Jennings: None. A. Velez: None. M. Porter: None. J. Turner: None. A.D. Coviello: Consultant; Current; Madrigal Pharmaceuticals, Inc. Advisory Panel; Current; Novo Nordisk. Consultant; Current; IQVIA Inc. Consultant; Ended; NewAmesterdamPharma. Consultant; Current; Wellworks for You, Inc, Hanmi Pharm. Co., Ltd.